RAPID MIGRAINE RELIEF WITH ALGINATE-BASED THIN FILM

ended

Klaria's business concept is based on developing and commercializing innovative, fast-acting medicinal products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. Migraine is the sixth most disabling illness in the world. The economic burden of migraine predominantly falls on patients and their employers in the form of bedridden days and lost productivity. The illness is three times as common in women than in men. However, existing drug delivery methods are not effective which results in low therapy satisfaction rates amongst migraine patients. Klaria developed an alginate-based polymer film capable of rapidly delivering the API (active pharmaceutical ingredient) directly into the bloodstream. The thin film is similar to a small postage stamp and is discreetly attached to the oral mucous membrane and allows the medication to be distributed into the bloodstream through the oral mucous membrane. The substance is delivered much more quickly (and thereby has a faster impact) than substances which are swallowed in tablets or capsules. Klaria’s film does not require taking an injection or suppository and ensures early intervention which is critical in order for migraine patients to experience pain relief. The film can be used by all migraine patients using medications based on triptans including those who experience concomitant vomiting during their migraine attack. Project RAPID, aims therefore to exploit the positive clinical performance of the buccal adhesive film, the company’s IP position and its ability to manufacture cost-effectively to launch an innovative migraine to contribute to an improved quality of life for migraine patients.